Vor Biopharma Appoints New Director, Discloses Officer Compensation
Ticker: VOR · Form: 8-K · Filed: Jul 22, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Jul 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation
TL;DR
Vor Bio adds a new board member, details on exec pay are coming.
AI Summary
Vor Biopharma Inc. announced on July 16, 2025, a change in its board of directors. Dr. Christopher Starr has been appointed as a new director, effective immediately. The company also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are crucial for understanding executive incentives.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and general disclosures about officer compensation, which are routine corporate events.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- Dr. Christopher Starr (person) — Newly appointed director
- July 16, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to Vor Biopharma's board?
Dr. Christopher Starr has been appointed as a new director.
What is the effective date of the new director's appointment?
The appointment of Dr. Christopher Starr is effective immediately as of July 16, 2025.
What other information is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements of certain officers.
What is Vor Biopharma Inc.'s state of incorporation?
Vor Biopharma Inc. is incorporated in Delaware.
What is the principal executive office address for Vor Biopharma Inc.?
The principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 22, 2025 by Dr. Christopher Starr regarding Vor Biopharma Inc. (VOR).